UNSPSC 51183506: Benfosformin anhydrous

This classification denotes the anhydrous form of an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49030P3C8S. European Medicines Agency schedules Benfosformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05715MIG. Benfosformin generally arises in the molecular formula C9H12N5O3P.2NA.H2O.

UNSPSC 51183506 Benfosformin anhydrous is a Commodity code for active pharmaceutical ingredients and finished generic drugs sold through state and local health systems, correctional facilities, and other public agencies via cooperative purchasing vehicles. State and local procurement under this code emphasizes multi-source generic pharmaceuticals and over-the-counter products distributed through authorized pharmaceutical wholesalers, with vendors required to meet cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with designated wholesalers, and offer pricing flexibility through multiple formats (flat price, net price, or WAC-minus structures). Issuing bodies include state health and human services departments, correctional systems, and municipalities participating in multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a significant buying vehicle for this category, consolidating demand across participating state and local government facilities in Minnesota and Oregon.

The Minnesota MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with a March 26, 2026 response deadline, illustrates current procurement activity under this code. The solicitation requires vendors to provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes, submit product information in designated CSV format, and demonstrate EDI capability. Awards are contingent on product availability by May 15, 2026, with resulting agreements effective July 1, 2026 and a two-year initial term for new responders. Evaluation weights pricing competitiveness at 75 percent, with remaining points allocated to fixed pricing structure, administrative fee compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must carry commercial general liability of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, and all products must comply with FDA requirements and maintain at least six-month shelf life. MMCAP reserves discretion to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.